![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C23H28O7 |
Molar mass | 416.470 g·mol−1 |
3D model (JSmol) | |
| |
|
Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity, [1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis. [2] [3]